Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poly ICLC - Oncovir

Drug Profile

Poly ICLC - Oncovir

Alternative Names: DNAJB1 PRKACA; Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acid

Latest Information Update: 24 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical University of South Carolina; Oncovir
  • Developer Abramson Cancer Center of the University of Pennsylvania; Augusta University; Bristol-Myers Squibb; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; Immatics N.V.; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); New York University School of Medicine; OncoQuest; Oncovir; Quest PharmaTech; Roswell Park Cancer Institute; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospitals of Geneva; University of Calgary; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Natural killer cell stimulants; Natural killer T cell stimulants; Proto oncogene protein c rel modulators; Proto oncogene protein c-ret modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer; Flavivirus infections; Orthopoxvirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Skin cancer; Solid tumours
  • Phase I/II B-cell lymphoma; Breast cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; HIV infections; Non-Hodgkin's lymphoma; Peritoneal cancer
  • Phase I COVID 2019 infections; Liver cancer; Mesothelioma; Pancreatic cancer; Prostate cancer
  • No development reported Acute myeloid leukaemia; Anaplastic astrocytoma; Chronic myelomonocytic leukaemia; Cytomegalovirus infections; Glioma; Influenza virus infections; Myelodysplastic syndromes; Smallpox

Most Recent Events

  • 03 Oct 2022 Parker Institute for Cancer Immunotherapy in collaboration with Nektar Therapeutics completes its phase I PORTER trial in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory, Second-line therapy or greater) in USA (IM) (NCT03835533)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IM, Injection)
  • 06 May 2022 Icahn School of Medicine at Mount Sinai and Oncovir, completes a phase I trial in Prostate cancer (Neoadjuvant therapy) in USA (IM) (NCT03262103)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top